go site 2/27 Friday
http://airbubbl.com/?gclid=EAIaIQobChMI38eYlYSJ3wIVJDPTCh0Xpw6-EAAYASAAEgLUCfD_BwE After a big February biotechs turned red today with major ETFs off about 1%.
In light of recent M&A talk about Pharmacyclics, Inc. (PCYC) at Market Cap of $16.6B we will look at other top Mid-Cap biopharmaceutical stocks for comparison to our motif below: ALNY, BMRN, INCY, MDVN, PBYI etc.
Bloomberg Report Drives Biotechs Higher
Pharmacyclics, Inc. (PCYC) is up $34, 16.2 % to $219 today on a Bloomberg report that the Company was up for sale with Johnson and Johnson (JNJ) and Novartis (NVS) as potential suitors. Although M&A is a major trend in healthcare there have not been any major acquisitions of mid-cap stocks with valuations higher than Onyxx buyout for $10.4B by Amgen, Inc. Pharmacyclics has a $15B market cap and was placed on our focus list at $38.20 on 6/8/12.
The Rayno Mid-Cap motif is a top performer up 27% YTD not including Cubist which was acquired recently for $101.9/share. The Rayno Mid-Cap portfolio consists of Alkermes (ALKS), Clovis Oncology (CLVS), Seattle Genetics (SGEN), Pharmacyclics (PCYC) and Vertex Pharmaceuticals (VRTX).
The Rayno Large Cap motif is up 8.9% YTD and our top ETF pick YTD the FBT is up 14.4% YTD.
Among our recent small cap speculative picks Celldex Therapeutics (CLDX) is up 42.6% YTD, Fibrocell Science (FCSC) up 86.1% YTD, Foundation Medicine (FMI) up 117% YTD and GlycoMimetics (GLYC) up 13.65 YTD .
Here is the Rayno Biopharma Portfolio Summary for 2014.